Abo Bibliothek: Guest
Critical Reviews™ in Oncogenesis

Erscheint 4 Ausgaben pro Jahr

ISSN Druckformat: 0893-9675

ISSN Online: 2162-6448

SJR: 0.395 SNIP: 0.322 CiteScore™:: 2.5 H-Index: 54

Indexed in

Colorectal Cancer Biology, Diagnosis, and Therapeutic Approaches

Volumen 25, Ausgabe 2, 2020, pp. 71-94
DOI: 10.1615/CritRevOncog.2020035067
Get accessGet access

ABSTRAKT

Colorectal cancer (CRC) is the second most diagnosed disease worldwide. It is the fourth leading cause of cancer related mortalities. Higher probability for the occurrence of CRC is due to western lifestyle, age, and personal history of chronic diseases. The development of CRC is a multistep process that includes a sequence of genetic, histological, and morphological alterations that accumulate over time. Furthermore, depending on the origin of mutations, CRC can be classified as familial, sporadic, and inherited, based on which a therapeutic plan is created for a CRC patient. These mutations cause chromosomal alterations and translocations in genes that lead to microsatellite instability (MSI), CpG island methylator phenotype (CIMP), and chromosomal instability (CIN). The mutations affect dysregulation of various pathways that are responsible for cancer progression. They include the PI3K/Akt, Wnt, TP53, and MAPK pathways. Mutated genes, such as KRAS, PTEN, SMAD4, BRAF, and PTEN, are employed as predictive biomarkers for early diagnosis. The conventional therapies of CRC start with surgical resection followed by adjuvant therapies, such as radiotherapy and chemotherapy. Researchers are now developing therapies that combine triplet drugs to overcome the hurdle of multidrug resistance (MDR). The combination of chemotherapy with immunotherapy to target the dysregulated proteins, such as EGFR and VEGFR is found efficient for advanced mCRC therapy. Researchers are now developing personalized medicines by detecting and validating key biomarkers to understand the mechanism of MDR and toxicity. In this review, we address genetic alterations, current data on biomarkers, and novel therapeutic approaches for the treatment of CRC.

SCHLÜSSELWÖRTER: CRC, biomarkers, MSI, CIMP, CIN, MDR, mCRC
REFERENZEN
  1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. Cancer J Clin. 2020;70:7-30.

  2. Schreuders EH, Wieten E, Kuipers EJ, Spaander MC. Optimizing fecal immunochemical testing for colorectal cancer screening. Clin Gastroenterol Hepatol. 2017;15:1498-9.

  3. Siegel RL, Miller KD, Fedewa SA, Ahnen DJ, Meester RG, Barzi A, Jemal A. Colorectal cancer statistics, 2017. CA: Cancer J Clin. 2017;67:177-93.

  4. Altobelli E, Rapacchietta L, Marziliano C, Campagna G, Profeta VF, Fagnano R. Differences in colorectal cancer surveillance epidemiology and screening in the WHO European Region. Oncol Lett. 2019;17:2531-42.

  5. Rawla P, Sunkara T, Barsouk A. Epidemiology of colorectal cancer: Incidence, mortality, survival, and risk factors. Przeglad Gastroenterologiczny. 2019;14:89.

  6. Hanahan D, Weinberg RA. Hallmarks of cancer: The next generation. Cell. 2011;144:646-74.

  7. Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nature Med. 2013;19:1423.

  8. Diehn M, Majeti R. Metastatic cancer stem cells: An opportunity for improving cancer treatment? Cell Stem Cell. 2010;6:502-3.

  9. Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology. 2010;138:2073-87.

  10. Issa J-PJ, Shen L, Toyota M. CIMP, at last. Gastroenterology. 2005;129:1121-4.

  11. Esteller M. Epigenetics in cancer. N Engl J Med. 2008;358:1148-59.

  12. Berman BP, Weisenberger DJ, Aman JF, Hinoue T, Ramjan Z, Liu Y, Noushmehr H, Lange CP, van Dijk CM, Tollenaar RA. Regions of focal DNA hypermethylation and long-range hypomethylation in colorectal cancer coincide with nuclear lamina-associated domains. Nature Genetics. 2012;44:40.

  13. Rubio C, Jaramillo E, Lindblom A, Fogt F. Classification of colorectal polyps: Guidelines for the endoscopist. Endoscopy. 2002;34:226-36.

  14. Willett CG, Chang DT, Czito BG, Meyer J, Wo J; Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487:330-7.

  15. Guinney J, Dienstmann R, Wang X, De Reynies A, Schlicker A, Soneson C, Marisa L, Roepman P, Nyamundanda G, Angelino P. The consensus molecular subtypes of colorectal cancer. Nature Med. 2015;21:1350-6.

  16. Hao H-X, Xie Y, Zhang Y, Charlat O, Oster E, Avello M, Lei H, Mickanin C, Liu D, Ruffner H. ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner. Nature. 2012;485:195-200.

  17. Karagiannis GS, Poutahidis T, Erdman SE, Kirsch R, Riddell RH, Diamandis EP. Cancer-associated fibroblasts drive the progression of metastasis through both paracrine and mechanical pressure on cancer tissue. Mol Cancer Res. 2012;10:1403-18.

  18. Cirri P, Chiarugi P. Cancer associated fibroblasts: The dark side of the coin. Am J Cancer Res. 2011;1:482.

  19. Hawinkels L, Paauwe M, Verspaget H, Wiercinska E, Van Der Zon J, Van Der Ploeg K, Koelink P, Lindeman J, Mesker W, Ten Dijke P. Interaction with colon cancer cells hyperactivates TGF-P signaling in cancer-associated fibroblasts. Oncogene. 2014;33:97-107.

  20. Gascard P, Tlsty TD. Carcinoma-associated fibroblasts: Orchestrating the composition of malignancy. Genes De-velop. 2016;30:1002-19.

  21. Hanley CJ, Mellone M, Ford K, Thirdborough SM, Mellows T, Frampton SJ, Smith DM, Harden E, Szyndralewiez C, Bullock M. Targeting the myofibroblasts cancer-associated fibroblast phenotype through inhibition of NOX4. J Natl Cancer Inst. 2018;110:109-20.

  22. Chen S-X, Xu X-E, Wang X-Q, Cui S-J, Xu L-L, Jiang Y-H, Zhang Y, Yan H-B, Zhang Q, Qiao J. Identification of colonic fibroblast secretomes reveals secretory factors regulating colon cancer cell proliferation. J Proteom. 2014;110:155-71.

  23. Augsten M. Cancer-associated fibroblasts as another polarized cell type of the tumor microenvironment. Front Oncol. 2014;4:62.

  24. Nishishita R, Morohashi S, Seino H, Wu Y, Yoshizawa T, Haga T, Saito K, Hakamada K, Fukuda S, Kijima H. Expression of cancer-associated fibroblast markers in advanced colorectal cancer. Oncol Lett. 2018;15: 6195-202.

  25. Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: From immunosurveillance to tumor escape. Nature Immunol. 2002;3:991-8.

  26. Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phases-elimination, equilibrium and escape. Curr Opin Immunol. 2014;27:16-25.

  27. de Visser KE, Coussens LM. The inflammatory tumor microenvironment and its impact on cancer development. In: Infection and inflammation: Impacts on oncogenesis. Basel, Switzerland: Karger Publishers; 2006. p.118-37.

  28. Suzuki S, Ichikawa Y, Nakagawa K, Kumamoto T, Mori R, Matsuyama R, Takeda K, Ota M, Tanaka K, Tamura T. High infiltration of mast cells positive to tryptase predicts worse outcome following resection of colorectal liver metastases. BMC Cancer. 2015;15:840.

  29. Arelaki S, Arampatzioglou A, Kambas K, Papagoras C, Miltiades P, Angelidou I, Mitsios A, Kotsianidis I, Skendros P, Sivridis E. Gradient infiltration of neutrophil extracellular traps in colon cancer and evidence for their involvement in tumour growth. PLoS One. 2016;11:e0154484.

  30. Pine J, Morris E, Hutchins G, West N, Jayne D, Quirke P, Prasad K. Systemic neutrophil-to-lymphocyte ratio in colorectal cancer: The relationship to patient survival, tumour biology and local lymphocytic response to tumour. Brit J Cancer. 2015;113:204-11.

  31. Cho H, Lim S-J, Won KY, Bae GE, Kim GY, Min JW, Noh B-j. Eosinophils in colorectal neoplasms associated with expression of CCL11 and CCL24. J Pathol Transl Med. 2016;50:45.

  32. Wei Y, Zhang X, Wang G, Zhou Y, Luo M, Wang S, Hong C. The impacts of pretreatment circulating eosinophils and basophils on prognosis of stage I-III colorectal cancer. Asia-Pacific J Clin Oncol. 2018;14:e243-51.

  33. Wei C, Yang C, Wang S, Shi D, Zhang C, Lin X, Liu Q, Dou R, Xiong B. Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis. Mol Cancer. 2019;18:64.

  34. Wang Y, Yin K, Tian J, Xia X, Ma J, Tang X, Xu H. Granulocytic myeloid-derived suppressor cells promote the stemness of colorectal cancer cells through exosomal S100A9. Adv Sci. 2019;6:1901278.

  35. Gajewski TF, Schreiber H, Fu Y-X. Innate and adaptive immune cells in the tumor microenvironment. Nat Immunol. 2013;14:1014.

  36. Zhang L-L, Zhang L-F, Shi Y-B. miR-24 inhibited the killing effect of natural killer cells to colorectal cancer cells by downregulating paxillin. Biomed Pharmacother. 2018;101:257-63.

  37. Facciabene A, Motz GT, Coukos G. T-regulatory cells: Key players in tumor immune escape and angiogenesis. Cancer Res. 2012;72:2162-71.

  38. Saito T, Nishikawa H, Wada H, Nagano Y, Sugiyama D, Atarashi K, Maeda Y, Hamaguchi M, Ohkura N, Sato E. Two FOXP3+ CD4+ T cell subpopulations distinctly control the prognosis of colorectal cancers. Nature Med. 2016;22:679.

  39. Mousa L, Salem ME, Mikhail S. Biomarkers of angiogenesis in colorectal cancer: Supplementary issue: Biomarkers for colon cancer. BIC. 2015;7:S25250.

  40. Dudley AC. Tumor endothelial cells. Cold Spring Harbor Perspect Med. 2012;2:a006536.

  41. Cima I, Kong SL, Sengupta D, Tan IB, Phyo WM, Lee D, Hu M, Iliescu C, Alexander I, Goh WL. Tumor-derived circulating endothelial cell clusters in colorectal cancer. Sci Transl Med. 2016;8:345ra389.

  42. Lu J, Ye X, Fan F, Xia L, Bhattacharya R, Bellister S, Tozzi F, Sceusi E, Zhou Y, Tachibana I. Endothelial cells promote the colorectal cancer stem cell pheno- type through a soluble form of Jagged-1. Cancer Cell. 2013;23:171-85.

  43. Zhang X, Yuan X, Shi H, Wu L, Qian H, Xu W. Exosomes in cancer: Small particle, big player. J Hematol Oncol. 2015;8:83.

  44. Chalmin F, Ladoire S, Mignot G, Vincent J, Bruchard M, Remy-Martin J-P, Boireau W, Rouleau A, Simon B, Lanneau D. Membrane-associated Hsp72 from tumor-derived exosomes mediates STAT3-dependent immunosuppres- sive function of mouse and human myeloid-derived suppressor cells. J Clin Invest. 2010;120:457-71.

  45. Zhang H-G, Grizzle WE. Exosomes: A novel pathway of local and distant intercellular communication that facilitates the growth and metastasis of neoplastic lesions. Am J Pathol. 2014;184:28-41.

  46. Hu J, Wang W, Lan X, Zeng Z, Liang Y, Yan Y, Song F, Wang F, Zhu X, Liao W. CAFs secreted exosomes promote metastasis and chemotherapy resistance by enhancing cell stemness and epithelial-mesenchymal transition in colorectal cancer. Mol Cancer. 2019;18:91.

  47. Chiodoni C, Colombo MP, Sangaletti S. Matricellular proteins: From homeostasis to inflammation, cancer, and metastasis. Cancer Metast Rev. 2010;29:295-307.

  48. Herzig DO, Tsikitis VL. Molecular markers for colon diagnosis, prognosis and targeted therapy. J Surg Oncol. 2015;111:96-102.

  49. Rennoll S, Yochum G. Regulation of MYC gene expression by aberrant Wnt/P-catenin signaling in colorectal cancer. World J Biol Chem. 2015;6:290.

  50. Toon CW, Chou A, Clarkson A, DeSilva K, Houang M, Chan JC, Sioson LL, Jankova L, Gill AJ. Immunohisto-chemistry for myc predicts survival in colorectal cancer. PLoS One. 2014;9.

  51. Chen J, Guo F, Shi X, Zhang L, Zhang A, Jin H, He Y. BRAF V600E mutation and KRAS codon 13 mutations predict poor survival in Chinese colorectal cancer patients. BMC Cancer. 2014;14:802.

  52. Li W, Qiu T, Zhi W, Shi S, Zou S, Ling Y, Shan L, Ying J, Lu N. Colorectal carcinomas with KRAS codon 12 mutation are associated with more advanced tumor stages. BMC Cancer. 2015;15:340.

  53. Day F, Muranyi A, Singh S, Shanmugam K, Williams D, Byrne D, Pham K, Palmieri M, Tie J, Grogan T. A mutant BRAF V600E-specific immunohistochemical assay: Correlation with molecular mutation status and clinical outcome in colorectal cancer. Target Oncol. 2015;10:99-109.

  54. Atreya CE, Sangale Z, Xu N, Matli MR, Tikishvili E, Welbourn W, Stone S, Shokat KM, Warren RS. PTEN expression is consistent in colorectal cancer primaries and metastases and associates with patient survival. Cancer Med. 2013;2:496-506.

  55. Sarli L, Bottarelli L, Bader G, Iusco D, Pizzi S, Costi R, Bertolani M, Roncoroni L, Bordi C. Association between recurrence of sporadic colorectal cancer, high level of microsatellite instability, and loss of heterozygosity at chromosome 18q. Dis Colon Rect. 2004;47:1467-82.

  56. Munro A, Lain S, Lane D. P53 abnormalities and outcomes in colorectal cancer: A systematic review. Brit J Cancer. 2005;92:434-44.

  57. Saslow D, Runowicz CD, Solomon D, Moscicki AB, Smith RA, Eyre HJ, Cohen C. American Cancer Society guideline for the early detection of cervical neoplasia and cancer. CA: Cancer J Clin. 2002;52:342-62.

  58. Mandel JS, Bond JH, Church TR, Snover DC, Bradley GM, Schuman LM, Ederer F. Reducing mortality from colorectal cancer by screening for fecal occult blood. N Engl J Med. 1993;328:1365-71.

  59. Schreuders EH, Grobbee EJ, Spaander MC, Kuipers EJ. Advances in fecal tests for colorectal cancer screening. Curr Treatment Options Gastroenterol. 2016;14:152-62.

  60. Johnson CD, Chen M-H, Toledano AY, Heiken JP, Dachman A, Kuo MD, Menias CO, Siewert B, Cheema JI, Obregon RG. Accuracy of CT colonography for detection of large adenomas and cancers. N Engl J Med. 2008;359:1207-17.

  61. Cheung AH-K, Chow C, To K-F. Latest development of liquid biopsy. J Thoracic Dis. 2018;10:S1645.

  62. Yamada T, Matsuda A, Koizumi M, Shinji S, Takahashi G, Iwai T, Takeda K, Ueda K, Yokoyama Y, Hara K. Liquid biopsy for the management of patients with colorectal cancer. Digestion. 2019;99:39-45.

  63. Giannopoulou L, Zavridou M, Kasimir-Bauer S, Lianidou ES. Liquid biopsy in ovarian cancer: The potential of circulating miRNAs and exosomes. Transl Res. 2019;205:77-91.

  64. Lhewa DY, Strate LL. Pros and cons of colonoscopy in management of acute lower gastrointestinal bleeding. World J Gastroenterol. 2012;18:1185.

  65. Poulogiannis G, Frayling IM, Arends MJ. DNA mismatch repair deficiency in sporadic colorectal cancer and Lynch syndrome. Histopathology. 2010;56:167-79.

  66. Grant M, Haydon A, Au L, Wilkins S, Oliva K, Segelov E, Antill Y, Carne P, Ranchod P, Polglase A. Immunohisto-chemistry testing for mismatch repair deficiency in Stage 2 colon cancer: A cohort study of two cancer centres. Int J Surg. 2018;51:71-5.

  67. Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, French AJ, Kabat B, Foster NR, Torri V. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28:3219.

  68. Karapetis CS, Khambata-Ford S, Jonker DJ, O'Callaghan CJ, Tu D, Tebbutt NC, Simes RJ, Chalchal H, Shapiro JD, Robitaille S. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359:1757-65.

  69. Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ, Juan T, Sikorski R, Suggs S, Radinsky R. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol. 2008;26:1626-34.

  70. Yao Z, Yaeger R, Rodrik-Outmezguine VS, Tao A, Torres NM, Chang MT, Drosten M, Zhao H, Cecchi F, Hembrough T. Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. Nature. 2017;548:234-8.

  71. Van Cutsem E, Kohne C-H, Lang I, Folprecht G, Nowacki MP, Cascinu S, Shchepotin I, Maurel J, Cunningham D, Tejpar S. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol. 2011;29:2011-9.

  72. Prasanna T, Karapetis CS, Roder D, Tie J, Padbury R, Price T, Wong R, Shapiro J, Nott L, Lee M. The survival outcome of patients with metastatic colorectal cancer based on the site of metastases and the impact of molecular markers and site of primary cancer on metastatic pattern. Act Oncol. 2018;57:1438-44.

  73. Venderbosch S, Nagtegaal ID, Maughan TS, Smith CG, Cheadle JP, Fisher D, Kaplan R, Quirke P, Seymour MT, Richman SD. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: A pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res. 2014;20:5322-30.

  74. Corcoran RB, Andre T, Atreya CE, Schellens JH, Yoshino T, Bendell JC, Hollebecque A, McRee AJ, Siena S, Middleton G. Combined BRAF, EGFR, and MEK inhibition in patients with BRAFV600E-mutant colorectal cancer. Cancer Discov. 2018;8:428-43.

  75. Van Cutsem E, Huijberts S, Grothey A, Yaeger R, Cuyle P-J, Elez E, Fakih M, Montagut C, Peeters M, Yoshino T. Binimetinib, encorafenib, and cetuximab triplet therapy for patients with BRAF V600E-mutant metastatic colorectal cancer: Safety leadin results from the phase III beacon colorectal cancer study. J Clin Oncol. 2019;37:1460-9.

  76. Goldberg KB, Blumenthal GM, McKee AE, Pazdur R. The FDA oncology center of excellence and precision medicine. Exper Biol Med. 2018;243:308-12.

  77. Chao M, Gibbs P. Caution is required before recommending routine carcinoembryonic antigen and imaging follow-up for patients with early-stage colon cancer. J Clin Oncol. 2009;27:e279-80.

  78. Baqar AR, Wilkins S, Staples M, Lee CHA, Oliva K, Mc-Murrick P. The role of preoperative CEA in the management of colorectal cancer: A cohort study from two cancer centres. Int J Surg. 2019;64:10-5.

  79. Hoskins JM, Goldberg RM, Qu P, Ibrahim JG, McLeod HL. UGT1A1 28 genotype and irinotecan-induced neutropenia: Dose matters. J Natl Cancer Inst. 2007; 99:1290-5.

  80. Amstutz U, Henricks LM, Offer SM, Barbarino J, Schellens JH, Swen JJ, Klein TE, McLeod HL, Caudle KE, Diasio RB. Clinical pharmacogenetics implementation consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther. 2018;103:210-6.

  81. Powell SM, Petersen GM, Krush AJ, Booker S, Jen J, Giardiello FM, Hamilton SR, Vogelstein B, Kinzler KW. Molecular diagnosis of familial adenomatous polyposis. N Engl J Med. 1993;329:1982-7.

  82. Calva-Cerqueira D, Chinnathambi S, Pechman B, Bair J, Larsen-Haidle J, Howe J. The rate of germline mutations and large deletions of SMAD4 and BMPR1A in juvenile polyposis. Clin Genet. 2009;75:79-85.

  83. Shiovitz S, Bertagnolli MM, Renfro LA, Nam E, Foster NR, Dzieciatkowski S, Luo Y, Lao VV, Monnat RJ Jr, Emond MJ. CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer. Gastroenterology. 2014;147:637-45.

  84. Di Nicolantonio F, Martini M, Molinari F, Sartore Bianchi A, Arena S, Saletti P, De Dosso S, Mazzucchelli L, Frattini M, Siena S. Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. J Clin Oncol. 2008.

  85. Murcia O, Juarez M, Rodriguez-Soler M, Hernandez-Illan E, Giner-Calabuig M, Alustiza M, Egoavil C, Castillejo A, Alenda C, Barbera V. Colorectal cancer molecular classification using BRAF, KRAS, microsatellite instability and CIMP status: Prognostic implications and response to chemotherapy. PLoS One. 2018;13:e0203051.

  86. Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature. 1998;396:643-9.

  87. Mouradov D, Domingo E, Gibbs P, Jorissen RN, Li S, Soo PY, Lipton L, Desai J, Danielsen HE, Oukrif D. Survival in stage II/III colorectal cancer is independently predicted by chromosomal and microsatellite instability, but not by specific driver mutations. Am J Gastroenterol. 2013;108:1785-93.

  88. Merlos-Suarez A, Barriga FM, Jung P, Iglesias M, Cespedes MV, Rossell D, Sevillano M, Hernando-Momblona X, da Silva-Diz V, Munoz P. The intestinal stem cell signature identifies colorectal cancer stem cells and predicts disease relapse. Cell Stem Cell. 2011;8:511-24.

  89. Fumagalli A, Oost KC, Kester L, Morgner J, Bornes L, Bruens L, Spaargaren L, Azkanaz M, Schelfhorst T, Beerling E. Plasticity of Lgr5-negative cancer cells drives metastasis in colorectal cancer. Cell Stem Cell. 2020.

  90. Tsai H-L, Pang S-Y, Wang H-C, Luo C-W, Li Q-L, Chen T-Y, Fang S-Y, Wang J-Y, Pan M-R. Impact of BMI1 expression on the apoptotic effect of paclitaxel in colorectal cancer. Am J Cancer Res. 2019;9:2544.

  91. Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer. 2005;5:845-56.

  92. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, Bartlett BR, Wang H, Luber B, Alani RM. Detection of circulating tumor DNA in early-and late-stage human malignancies. Sci Transl Med. 2014;6:224ra224.

  93. Fleshner P, Braunstein GD, Ovsepyan G, Tonozzi TR, Kammesheidt A. Tumor-associated DNA mutation detection in individuals undergoing colonoscopy. Cancer Med. 2018;7:167-74.

  94. Molnar B, Galamb O, Kalmar A, Bartak BK, Nagy ZB, Toth K, Tulassay Z, Igaz P, Dank M. Circulating cell-free nucleic acids as biomarkers in colorectal cancer screening and diagnosis-an update. Expert Rev. Mol Diagnostics. 2019;19:477-98.

  95. Hardingham JE, Hewett PJ, Sage RE, Finch JL, Nuttall JD, Kotasek D, Dobrovic A. Molecular detection of blood-borne epithelial cells in colorectal cancer patients and in patients with benign bowel disease. Int J Cancer. 2000;89:8-13.

  96. Lim SH, Becker TM, Chua W, Ng W, de Souza P, Spring KJ. Circulating tumour cells and the epithelial mesenchymal transition in colorectal cancer. J Clin Pathol. 2014;67:848-53.

  97. Marcuello M, Vymetalkova V, Neves RP, Duran-Sanchon S, Vedeld HM, Tham E, van Dalum G, Flugen G, Garcia-Barberan V, Fijneman RJ. Circulating biomarkers for early detection and clinical management of colorectal cancer. Mol Aspect Med. 2019 Oct 1;69:107-22.

  98. Musella V, Pietrantonio F, Di Buduo E, Iacovelli R, Martinetti A, Sottotetti E, Bossi I, Maggi C, Di Bartolomeo M, De Braud F. Circulating tumor cells as a longitudinal bio-marker in patients with advanced chemorefractory, RAS-BRAF wild-type colorectal cancer receiving cetuximab or panitumumab. Int J Cancer. 2015;137:1467-74.

  99. Wang Z-H, Ren L-L, Zheng P, Zheng H-M, Yu Y-N, Wang J-L, Lin Y-W, Chen Y-X, Ge Z-Z, Chen X-Y. miR-194 as a predictor for adenoma recurrence in patients with advanced colorectal adenoma after polypectomy. Cancer Prevent Res. 2014;7:607-16.

  100. Liu T, Zhang X, Du L, Wang Y, Liu X, Tian H, Wang L, Li P, Zhao Y, Duan W. Exosome-transmitted miR-128-3p in-creases chemosensitivity of oxaliplatin-resistant colorectal cancer. Mol Cancer. 2019;18:43.

  101. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509-20.

  102. Ma B, Gao P, Wang H, Xu Q, Song Y, Huang X, Sun J, Zhao J, Luo J, Sun Y. What has preoperative radio (chemo) therapy brought to localized rectal cancer patients in terms of perioperative and long-term outcomes over the past decades? A systematic review and meta-analysis based on 41,121 patients. Int J Cancer. 2017;141:1052-65.

  103. Aapro M, Beguin Y, Bokemeyer C, Dicato M, Gascon P, Glaspy J, Hofmann A, Link H, Littlewood T, Ludwig H. Management of anaemia and iron deficiency in patients with cancer: ESMO clinical practice guidelines. Ann Oncol. 2018;29:iv96-110.

  104. Franzese C, Comito T, Toska E, Tozzi A, Clerici E, De Rose F, Franceschini D, Navarria P, Reggiori G, Tomatis S. Predictive factors for survival of oligometastatic colorectal cancer treated with stereotactic body radiation therapy. Radiother Oncol. 2019;133:220-6.

  105. Dell'Acqua V, Surgo A, Kraja F, Kobiela J, Zerella MA, Spychalski P, Gandini S, Francia C, Ciardo D, Fodor C. Stereotactic radiation therapy in oligometastatic colorectal cancer: Outcome of 102 patients and 150 lesions. Clin Exper Meta. 2019;36:331-42.

  106. Joo JH, Park J-H, Kim JC, Yu CS, Lim S-B, Park IJ, Kim TW, Hong YS, Kim K-P, Yoon SM. Local control outcomes using stereotactic body radiation therapy for liver metastases from colorectal cancer. Int J Rad Oncol Biol Phys. 2017;99:876-83.

  107. Stintzing S, Tejpar S, Gibbs P, Thiebach L, Lenz H-J. Understanding the role of primary tumour localisation in colorectal cancer treatment and outcomes. Eur J Cancer. 2017;84:69-80.

  108. Gibbs P, Heinemann V, Sharma NK, Taieb J, Ricke J, Peeters M, Findlay M, Robinson B, Jackson C, Strickland A. Effect of primary tumor side on survival outcomes in untreated patients with metastatic colorectal cancer when selective internal radiation therapy is added to chemotherapy: Combined analysis of two randomized controlled studies. Clin Colorect Cancer. 2018;17:e617-29.

  109. Ruhl R, Rana S, Kelley K, Espinosa-Diez C, Hudson C, Lanciault C, Thomas CR, Tsikitis VL, Anand S. microR-NA-451a regulates colorectal cancer proliferation in response to radiation. BMC Cancer. 2018;18:517.

  110. Goldberg RM, Rothenberg ML, Van Cutsem E, Benson AB III, Blanke CD, Diasio RB, Grothey A, Lenz H-J, Meropol NJ, Ramanathan RK. The continuum of care: A paradigm for the management of metastatic colorectal cancer. Oncologist. 2007;12:38-50.

  111. Biagi JJ, Raphael MJ, Mackillop WJ, Kong W, King WD, Booth CM. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: A systematic review and meta-analysis. JAMA. 2011;305:2335-42.

  112. Sargent D, Shi Q, Yothers G, Van Cutsem E, Cassidy J, Saltz L, Wolmark N, Bot B, Grothey A, Buyse M. Two or three year disease-free survival (DFS) as a primary endpoint in stage III adjuvant colon cancer trials with fluoro-pyrimidines with or without oxaliplatin or irinotecan: Data from 12,676 patients from MOSAIC, X-ACT, PETACC-3, C-06, C-07 and C89803. Eur J Cancer. 2011;47:990-6.

  113. Shi T, Gao M, He M, Yue F, Zhao Y, Sun M, He K, Chen L. 5-FU preferably induces apoptosis in BRAF V600E colorectal cancer cells via downregulation of Bcl-x L. Mol Cell Biochem. 2019;461:151-8.

  114. Liu F, Ai FY, Zhang DC, Tian L, Yang ZY, Liu SJ. Ln-cRNA NEAT1 knockdown attenuates autophagy to elevate 5-FU sensitivity in colorectal cancer via targeting miR-34a. Cancer Med. 2020;9:1079-91.

  115. Wang Z, Dai W-P, Zang Y-S. Complete response with fluorouracil and irinotecan with a BraFV600e and eGFr inhibitor in BraF-mutated metastatic colorectal cancer: A case report. OncoTargets Ther. 2019;12:443.

  116. Fujii H, Yamada Y, Watanabe D, Matsuhashi N, Takahashi T, Yoshida K, Suzuki A. Dose adjustment of irinotecan based on UGT1A1 polymorphisms in patients with colorectal cancer. Cancer Chemother Pharmacol. 2019;83:123-9.

  117. Buck E, Sprick M, Gaida MM, Grullich C, Weber TF, Herpel E, Bruckner T, Koschny R. Tumor response to irinotecan is associated with CYP3A5 expression in colorectal cancer. Oncol Lett. 2019;17:3890-8.

  118. Augustine T, Maitra R, Zhang J, Nayak J, Goel S. Sensitization of colorectal cancer to irinotecan therapy by PARP inhibitor rucaparib. Invest New Drugs. 2019;37:948-60.

  119. Petrelli F, Cabiddu M, Barni S. 5-fluorouracil or capecitabine in the treatment of advanced colorectal cancer: A pooled analysis of randomized trials. Med Oncol. 2012;29:1020-9.

  120. Hsu HH, Chen MC, Baskaran R, Lin YM, Day CH, Lin YJ, Tu CC, Vijaya Padma V, Kuo WW, Huang CY. Oxaliplatin resistance in colorectal cancer cells is mediated via activation of ABCG2 to alleviate ER stress induced apoptosis. J Cell Physiol. 2018;233:5458-67.

  121. Galaine J, Turco C, Vauchy C, Royer B, Mercier-Letondal P, Queiroz L, Loyon R, Mouget V, Boidot R, Laheurte C. CD4 T cells target colorectal cancer antigens upregulated by oxaliplatin. Int J Cancer. 2019;145:3112-25.

  122. Arnold D. Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. Strahlentherapie Onkologie: Organ Deutschen Rontgengesellschaft. 2012;188:196-7 (in German).

  123. Kuebler JP, Wieand HS, O'Connell MJ, Smith RE, Colangelo LH, Yothers G, Petrelli NJ, Findlay MP, Seay TE, Atkins JN. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: Results from NSABP C-07. J Clin Oncol. 2007;25:2198-204.

  124. Andre T, Boni C, Navarro M, Tabernero J, Hickish T, Topham C, Bonetti A, Clingan P, Bridgewater J, Rivera F. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27:3109-16.

  125. Ribecco AS, Pino MS, Cipriani G, Marinozzi C, Fioretto L. Molecularly targeted therapy: Toxicity and quality of life considerations in advanced colorectal cancer. Exp Rev Anticancer Ther. 2013;13:1181-91.

  126. Choong MK, Tsafnat G. Genetic and epigenetic biomarkers of colorectal cancer. Clin Gastroenterol Hepatol. 2012;10:9-15.

  127. Colucci G, Gebbia V, Paoletti G, Giuliani F, Caruso M, Gebbia N, Carteni G, Agostara B, Pezzella G, Manzione L. Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: A multicenter study of the Gruppo Oncologico Dell'Italia Meridionale. J Clin Oncol. 2005;23:4866-75.

  128. Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol. 2004;22:229-37.

  129. Falcone A, Masi G, Allegrini G, Danesi R, Pfanner E, Brunetti IM, Di Paolo A, Cupini S, Del Tacca M, Conte P. Biweekly chemotherapy with oxaliplatin, irinotecan, infusional fluorouracil, and leucovorin: A pilot study in patients with metastatic colorectal cancer. J Clin Oncol. 2002;20:4006-14.

  130. Masi G, Allegrini G, Cupini S, Marcucci L, Cerri E, Brunetti I, Fontana E, Ricci S, Andreuccetti M, Falcone A. First-line treatment of metastatic colorectal cancer with irinotecan, oxaliplatin and 5-fluorouracil/leucovorin (FOLFOXIRI): Results of a phase II study with a simpli-fied biweekly schedule. Ann Oncol. 2004;15:1766-72.

  131. Falcone A, Ricci S, Brunetti I, Pfanner E, Allegrini G, Barbara C, Crino L, Benedetti G, Evangelista W, Fanchini L. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOL-FIRI) as first-line treatment for metastatic colorectal cancer: The Gruppo Oncologico Nord Ovest. J Clin Oncol. 2007;25:1670-6.

  132. Toubaji A, Achtar M, Provenzano M, Herrin VE, Behrens R, Hamilton M, Bernstein S, Venzon D, Gause B, Marincola F. Pilot study of mutant ras peptide-based vaccine as an adjuvant treatment in pancreatic and colorectal cancers. Cancer Immunol Immunother. 2008;57:1413-20.

  133. Zhang Y, Ma J-A, Zhang H-X, Jiang Y-N, Luo W-H. Cancer vaccines: Targeting KRAS-driven cancers. Exp Rev Vaccines. 2020;19:163-73.

  134. Kim VM, Pan X, Soares KC, Azad NS, Ahuja N, Gamper CJ, Blair AB, Muth S, Ding D, Ladle BH. Neoantigen-based EpiGVAX vaccine initiates antitumor immunity in colorectal cancer. JCI Insight. 2020;5:e136368.

  135. Fan J, Shang D, Han B, Song J, Chen H, Yang J-M. Adoptive cell transfer: Is it a promising immunotherapy for colorectal cancer? Theranostics. 2018;8:5784.

  136. Veigl ML, Kasturi L, Olechnowicz J, Ma A, Lutterbaugh JD, Periyasamy S, Li G-M, Drummond J, Modrich PL, Sedwick WD. Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc Natl Acad Sci U S A. 1998;95:8698-702.

  137. Overman MJ, McDermott R, Leach JL, Lonardi S, Lenz H-J, Morse MA, Desai J, Hill A, Axelson M, Moss RA. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): An open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18:1182-91.

  138. Overman MJ, Lonardi S, Wong KYM, Lenz H-J, Gelsomino F, Aglietta M, Morse MA, Van Cutsem E, McDermott R, Hill A. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018;36:773-9.

  139. Hochster HS, Bendell JC, Cleary JM, Foster P, Zhang W, He X, Hernandez G, Iizuka K, Eckhardt SG. Efficacy and safety of atezolizumab (Atezo) and bevacizumab (Bev) in a phase Ib study of microsatellite instability (MSI)-high metastatic colorectal cancer (mCRC). J Clin Oncol. 2017;35:673.

  140. Gong C. Inventory of progress in the treatment of colorectal cancer in 2018. E-J Comprehen Cancer Treat. 2019 Feb 15;5(1):5-14 (in Chinese).

  141. Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB III. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: Results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25:1539-44.

  142. Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004;350:2335-42.

  143. Douillard J-Y, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated meta-static colorectal cancer: The PRIME study. J Clin Oncol. 2010;28:4697-705.

  144. Misale S, Di Nicolantonio F, Sartore-Bianchi A, Siena S, Bardelli A. Resistance to anti-EGFR therapy in colorectal cancer: From heterogeneity to convergent evolution. Cancer Disc. 2014;4:1269-80.

  145. Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis. Acta Oncol. 2014;53:852-64.

  146. Braicu C, Mehterov N, Vladimirov B, Sarafian V, Nabavi SM, Atanasov AG, Berindan-Neagoe I. Nutrigenomics in cancer: Revisiting the effects of natural compounds. Semin Cancer Biol. 2017;46:84-106.

  147. Catana C-S, Atanasov AG, Berindan-Neagoe I. Natural products with anti-aging potential: Affected targets and molecular mechanisms. Biotechnol Adv. 2018;36:1649-56.

  148. Zhang J, Feng Z, Wang C, Zhou H, Liu W, Kanchana K, Dai X, Zou P, Gu J, Cai L. Curcumin derivative WZ35 efficiently suppresses colon cancer progression through inducing ROS production and ER stress-dependent apoptosis. Am J Cancer Res. 2017;7:275.

  149. Sufi SA, Adigopula LN, Syed SB, Mukherjee V, Coumar MS, Rao HSP, Rajagopalan R. In-silico and in-vitro anticancer potential of a curcumin analogue (1E, 6E)-1, 7-di (1H-indol-3-yl) hepta-1, 6-diene-3, 5-dione. Biomed Pharmacother. 2017;85:389-98.

  150. Waghela BN, Sharma A, Dhumale S, Pandey SM, Pathak C. Curcumin conjugated with PLGA potentiates sustainability, anti-proliferative activity and apoptosis in human colon carcinoma cells. PLoS One. 2015;10:e0117526.

  151. Zhao Y, Fan D, Zheng ZP, Li ET, Chen F, Cheng KW, Wang M. 8-C-(E-phenylethenyl) quercetin from onion/ beef soup induces autophagic cell death in colon cancer cells through ERK activation. Mol Nutr Food Res. 2017;61:1600437.

  152. European Science Foundation (ESF). Nanomedicine: An ESF-European Medical Research Councils (EMRC) forward look report. Strasbourg, France: Cedex; 2004.

  153. Mishra B, Chaurasia S. Design of novel chemotherapeutic delivery systems for colon cancer therapy based on oral polymeric nanoparticles. Therapeut Del. 2017;8:29-47.

  154. Zupancic E, Peres C, I Matos A, Lopes J, Moreira JN, Gaspar RS, Florindo HF. Translational peptide-associated nanosystems: Promising role as cancer vaccines. Curr Topics Med Chem. 2016;16:291-313.

  155. Blau R, Krivitsky A, Epshtein Y, Satchi-Fainaro R. Are nanotheranostics and nanodiagnostics-guided drug delivery stepping stones towards precision medicine? Drug Resist Updates. 2016;27:39-58.

  156. Kim D-H. Image-guided cancer nanomedicine. J Image. 2018;4:18.

  157. Maybin JA, Battersby S, Hiram N, Nikitenko LL, Critchley HO, Jabbour HN. The expression and regulation of adrenomedullin in the human endometrium: A candidate for endometrial repair. Endocrinology. 2011;152:2845-56.

  158. Chen M, Liang X, Gao C, Zhao R, Zhang N, Wang S, Chen W, Zhao B, Wang J, Dai Z. Ultrasound triggered conversion of porphyrin/camptothecin-fluoroxyuridine triad microbubbles into nanoparticles overcomes multidrug resistance in colorectal cancer. ACS Nano. 2018;12:7312-26.

  159. Guo J, Yu Z, Das M, Huang L. Nano codelivery of oxaliplatin and folinic acid achieves synergistic chemo-immunotherapy with 5-fluorouracil for colorectal cancer and liver metastasis. ACS Nano. 2020;14:5075-89.

  160. Hesse C, Kollenda S, Rotan O, Pastille E, Adamczyk A, Wenzek C, Hansen W, Epple M, Buer J, Westendorf AM. A tumor-peptide-based nanoparticle vaccine elicits efficient tumor growth control in antitumor immunotherapy. Mol Cancer Therapeut. 2019;18:1069-80.

  161. Li Y, Du Y, Liang X, Sun T, Xue H, Tian J, Jin Z. EGFR-targeted liposomal nanohybrid cerasomes: Theranostic function and immune checkpoint inhibition in a mouse model of colorectal cancer. Nanoscale. 2018;10:16738-49.

  162. Sesarman A, Tefas L, Sylvester B, Licarete E, Rauca V, Luput L, Patras L, Banciu M, Porfire A. Anti-angiogenic and anti-inflammatory effects of long-circulating liposomes co-encapsulating curcumin and doxorubicin on C26 murine colon cancer cells. Pharmacol Rep. 2018; 70:331-9.

  163. Javadi S, Rostamizadeh K, Hejazi J, Parsa M, Fathi M. Curcumin mediated down-regulation of aVp3 integrin and up-regulation of pyruvate dehydrogenase kinase 4 (PDK4) in erlotinib resistant SW480 colon cancer cells. Phytother Res. 2018;32:355-64.

  164. Marjaneh RM, Rahmani F, Hassanian SM, Rezaei N, Hashemzehi M, Bahrami A, Ariakia F, Fiuji H, Sahebkar A, Avan A. Phytosomal curcumin inhibits tumor growth in colitis-associated colorectal cancer. J Cell Physiol. 2018;233:6785-98.

  165. Kamal R, Chadha VD, Dhawan D. Physiological uptake and retention of radiolabeled resveratrol loaded gold nanoparticles (99mTc-Res-AuNP) in colon cancer tissue. Nanomed Nanotechnol Biol Med. 2018;14:1059-71.

REFERENZIERT VON
  1. Sadat Sams M. A., Wuest Melinda, Paiva Igor M., Munira Sirazum, Sarrami Nasim, Sanaee Forughalsadat, Yang Xiaoyan, Paladino Marco, Binkhathlan Ziyad, Karimi-Busheri Feridoun, Martin Gary R., Jirik Frank R., Murray David, Gamper Armin M., Hall Dennis G., Weinfeld Michael, Lavasanifar Afsaneh, Nano-Delivery of a Novel Inhibitor of Polynucleotide Kinase/Phosphatase (PNKP) for Targeted Sensitization of Colorectal Cancer to Radiation-Induced DNA Damage, Frontiers in Oncology, 11, 2021. Crossref

  2. Palmieri Giuseppe, Rozzo Carla Maria, Colombino Maria, Casula Milena, Sini Maria Cristina, Manca Antonella, Pisano Marina, Doneddu Valentina, Paliogiannis Panagiotis, Cossu Antonio, Are Molecular Alterations Linked to Genetic Instability Worth to Be Included as Biomarkers for Directing or Excluding Melanoma Patients to Immunotherapy?, Frontiers in Oncology, 11, 2021. Crossref

  3. Cerrito Maria Grazia, Grassilli Emanuela, Identifying Novel Actionable Targets in Colon Cancer, Biomedicines, 9, 5, 2021. Crossref

  4. Sheik Aliya, Kim Kwanwoo, Varaprasad Ganji Lakshmi, Lee Hoomin, Kim Suheon, Kim Eunsu, Shin Jin-Yong, Oh Seo Yeong, Huh Yun Suk, The anti-cancerous activity of adaptogenic herb Astragalus membranaceus, Phytomedicine, 91, 2021. Crossref

  5. Chalikonda Gayathri, Lee Hoomin, Sheik Aliya, Huh Yun Suk, Targeting key transcriptional factor STAT3 in colorectal cancer, Molecular and Cellular Biochemistry, 476, 9, 2021. Crossref

  6. Akram Abdulrazzaq Ammar, Sulaiman Hamid Sana, Al-Douri Asaad T., Hamad Mohamad A. A., Selvi D., Mohamed Ibrahim Abdelrahman, Pandian Sivakumar, Hyperspectral Image Analysis of Colon Tissue and Deep Learning for Characterization of Health care, Journal of Environmental and Public Health, 2022, 2022. Crossref

  7. Forouzesh Flora, Kia Fatemeh Sadat, Nazemalhosseini-Mojarad Ehsan, BidSi6 and BidEL isoforms as a potential marker for predicting colorectal adenomatous polyps, BMC Medical Genomics, 15, 1, 2022. Crossref

  8. Dong Kechen, Liu Jianping, Zhou Wei, Zhang Guanglin, Exploring the Relationship Between Senescence and Colorectal Cancer in Prognosis, Immunity, and Treatment, Frontiers in Genetics, 13, 2022. Crossref

  9. de Biase Dario, Malapelle Umberto, De Leo Antonio, Maloberti Thais, Visani Michela, Pisapia Pasquale, Acquaviva Giorgia, Pepe Francesco, Russo Gianluca, Iaccarino Antonino, Pession Annalisa, Tallini Giovanni, Troncone Giancarlo, Multi-gene custom panels for the characterisation of metastatic colorectal carcinoma in clinical practice: express the role of PIK3CA mutations, Journal of Clinical Pathology, 75, 7, 2022. Crossref

  10. Mesa Francisco, Mesa-López Maria José, Egea-Valenzuela Juan, Benavides-Reyes Cristina, Nibali Luigi, Ide Mark, Mainas Giuseppe, Rizzo Manfredi, Magan-Fernandez Antonio, A New Comorbidity in Periodontitis: Fusobacterium nucleatum and Colorectal Cancer, Medicina, 58, 4, 2022. Crossref

  11. Pączek Sara, Łukaszewicz-Zając Marta, Mroczko Barbara, Granzymes—Their Role in Colorectal Cancer, International Journal of Molecular Sciences, 23, 9, 2022. Crossref

  12. Wang Dan, Li Yin, Liu Yanling, Cheng Shuyu, Liu Fan, Zuo Renjie, Ding Chenchun, Shi Songlin, Liu Guoyan, NPM1 promotes cell proliferation by targeting PRDX6 in colorectal cancer, The International Journal of Biochemistry & Cell Biology, 147, 2022. Crossref

  13. Hu Jun, Tian Caijuan, Zhao Yanpeng, Guo Yixian, Chen Shuo, Prognostic prediction of systemic immune-inflammation status for patients with colorectal cancer: a novel pyroptosis-related model, World Journal of Surgical Oncology, 20, 1, 2022. Crossref

  14. Feng Wen-Ming, Gong Hui, Wang Yong-Chun, Wang Yao, Xue Tao, Zhang Ting, Cui Ge, NudCD1 as a prognostic marker in colorectal cancer and its role in the upregulation of cellular spindle assembly checkpoint genes and LIS1 pathways, BMC Cancer, 22, 1, 2022. Crossref

  15. Huang Yanpeng, Zhou Jinming, Zhong Haibin, Xie Ning, Zhang Fei-Ran, Zhang Zhanmin, Identification of a novel lipid metabolism-related gene signature for predicting colorectal cancer survival, Frontiers in Genetics, 13, 2022. Crossref

  16. Liu Hua, Chen Biao, Liu Lian-Lin, Cong Lin, Cheng Yong, The role of MARCH9 in colorectal cancer progression, Frontiers in Oncology, 12, 2022. Crossref

Digitales Portal Digitale Bibliothek eBooks Zeitschriften Referenzen und Berichte Forschungssammlungen Preise und Aborichtlinien Begell House Kontakt Language English 中文 Русский Português German French Spain